Loading...
In this study, patients receiving ddI + d4T + HU had a nearly 8-fold greater risk for neuropathy compared with those receiving ddI alone.
The role of hydroxyurea (HU) as an adjunct to antiretroviral therapy is still being defined. Researchers from the Johns Hopkins AIDS Service, which has collected longitudinal patient data since 1990, raise new concerns about HU's toxicity. As in other reports from this group, the cohort was predominantly male (72%) and African American (75%), with 47% reporting intravenous drug use as their risk factor for HIV transmission.
The goal of the study was to define the risk of neuropathy in patients receiving d4T and ddI alone and in combination, with and without HU. Included in the analysis were 1116 patients wh…